Literature DB >> 1566911

5-Hydroxytryptamine potentiates vasoconstrictor effect of endothelin-1.

B C Yang1, W W Nichols, D L Lawson, J L Mehta.   

Abstract

Interactions between 5-hydroxytryptamine (5-HT) and endothelin-1 (ET-1) relative to contraction of rat aortic rings were examined in this study. Pretreatment of rings with threshold concentration of 5-HT potentiated the subsequent contractile response to ET-1. However, pretreatment with threshold concentration of ET-1 did not potentiate the contractile response to 5-HT. The 5-HT receptor antagonist LY 53857 blocked the synergistic contractile effects of 5-HT and ET-1 on rat aortic rings. Indomethacin and the thromboxane A2/endoperoxide receptor antagonist SQ 29548 also attenuated (P less than 0.05) the synergistic contractile effects of 5-HT and ET-1, suggesting release of thromboxane A2 or expression of thromboxane A2 receptors during this interaction. The calcium channel blocker verapamil also decreased the synergistic contractile effects of 5-HT and ET-1. Contraction of aortic rings by 5-HT alone was abolished by LY 53857 and attenuated by verapamil, diltiazem, and SQ 29548. Decrease in the force of contraction by verapamil as well as diltiazem indicates activation of voltage-dependent calcium channels during 5-HT-mediated contraction and perhaps during amplification of the vasoconstrictor activity of ET-1 by 5-HT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1566911     DOI: 10.1152/ajpheart.1992.262.4.H931

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  Effects of a new calcium antagonist, CD-832, on experimental coronary artery spasm in miniature pigs.

Authors:  T Takahashi; T Fukai; H Hata; H Kasuya; T Kuga; K Egashira; A Takeshita
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

2.  Potentiation by endothelin-1 of 5-hydroxytryptamine responses in aortae from streptozotocin-diabetic rats: a role for thromboxane A2.

Authors:  G M James; W C Hodgson
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.